Aziz K. Nakhanov
Research Subjects
Aziz K. Nakhanov has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Kamshat Abithanovna Shorayeva
Research Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan
8 shared publications - Olga V. Chervyakova
Research Institute for Biological Safety Problems, Ministry of Health of the Republic of Kazakhstan, Gvardeysky Settlement, Korday District, Zhambyl Region, Republic of Kazakhstan; National Holding “QazBioPharm”, Republic of Kazakhstan
7 shared publications - Mukhit B. Orynbayev
Research Institute for Biological Safety Problems, National Holding QazBioPharm, The Ministry of Health care of the Republic of Kazakhstan, Gvardeiskiy 080409, Kazakhstan
5 shared publications - Nurlan S. Kozhabergenov
Research Institute for Biological Safety Problems, National Holding QazBioPharm, The Ministry of Health care of the Republic of Kazakhstan, Gvardeiskiy 080409, Kazakhstan
5 shared publications - Bolat Yespembetov
LLP «Research Institute for Biological Safety Problems», National holding «QazBioPharm
4 shared publications - Markhabat Kassenov
Kazakh Scientific Research Veterinary Institute, Kazakhstan
4 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1124
Phage-Derived Antimicrobial Strategies Against Treponema pallidum: Genomic Evidence, Biological Barriers, and Translational Roadmap
Syphilis is a systemic sexually transmitted infection caused by Treponema pallidum subsp. pallidum. Despite effective penicillin-based therapy, it remains a major public health challenge due to ongoing transmission, latent infection, congenital disease, and the lack of a licensed vaccine. While the resurgence of bacteriophage research has stimulated interest in alternative antimicrobials for sexually transmitted infections, direct extrapolation of classical lytic phage therapy to T. pallidum is premature. This pathogen is experimentally demanding, grows slowly, lacks validated lytic phages, and possesses an unusual outer membrane with sparse surface-exposed targets. However, comparative genomics has identified prophage-like elements in several Treponema species, while the T. pallidum-lineage genomes examined by Ridgway et al. did not contain detectable prophage regions. This shifts the rationale from endogenous T. pallidum prophage exploitation toward cautious evaluation of heterologous treponemal phage-derived modules, with cross-species target compatibility as a central requirement. This review critically evaluates phage-derived strategies against T. pallidum, discussing biological barriers, prophage genomics, candidate modalities, biosafety filters, and regulatory considerations. We propose a staged translational roadmap progressing from evidence appraisal and candidate prioritization to biochemical validation, direct T. pallidum testing, ex vivo assessment, in vivo validation, and product-class-specific development. Currently, the most credible outputs of this field are research tools, diagnostic binding modules, and early antimicrobial prototypes rather than clinical phage therapy for syphilis.
- 11 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1124
Open AccessPhage-Derived Antimicrobial Strategies Against Treponema pallidum: Genomic Evidence, Biological Barriers, and Translational Roadmap
Syphilis is a systemic sexually transmitted infection caused by Treponema pallidum subsp. pallidum. Despite effective penicillin-based therapy, it remains a major public health challenge due to ongoing transmission, latent infection, congenital disease, and the lack of a licensed vaccine. While the resurgence of bacteriophage research has stimulated interest in alternative antimicrobials for sexually transmitted infections, direct extrapolation of classical lytic phage therapy to T. pallidum is premature. This pathogen is experimentally demanding, grows slowly, lacks validated lytic phages, and possesses an unusual outer membrane with sparse surface-exposed targets. However, comparative genomics has identified prophage-like elements in several Treponema species, while the T. pallidum-lineage genomes examined by Ridgway et al. did not contain detectable prophage regions. This shifts the rationale from endogenous T. pallidum prophage exploitation toward cautious evaluation of heterologous treponemal phage-derived modules, with cross-species target compatibility as a central requirement. This review critically evaluates phage-derived strategies against T. pallidum, discussing biological barriers, prophage genomics, candidate modalities, biosafety filters, and regulatory considerations. We propose a staged translational roadmap progressing from evidence appraisal and candidate prioritization to biochemical validation, direct T. pallidum testing, ex vivo assessment, in vivo validation, and product-class-specific development. Currently, the most credible outputs of this field are research tools, diagnostic binding modules, and early antimicrobial prototypes rather than clinical phage therapy for syphilis.
- Open Access
- 4 November 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (11) , 2542
Integrated Molecular and Serological Epizootic Monitoring of SARS-CoV-2 and Influenza A Virus in Animals in Kazakhstan
Respiratory viruses with broad host ranges are relevant to veterinary epidemiology, biological safety, and One Health surveillance. This retrospective study integrated companion-animal and wildlife records to examine two complementary surveillance questions: SARS-CoV-2 detection in dogs and cats with close human contact, and influenza A virus detection across a broader multispecies panel that included wild birds. We analyzed 256 archived animal samples collected in Kazakhstan during 2022–2023, comprising 158 dogs, 76 cats, and 22 animals of other domestic and wild species. A previously developed in-house multiplex RT-qPCR assay was used to detect SARS-CoV-2 and influenza A virus RNA, and a previously developed in-house SM-antigen-based ELISA was used to assess SARS-CoV-2-associated serum reactivity. SARS-CoV-2 RNA was detected in 104/256 samples (40.6%; 95% CI, 34.8–46.7), including 68 dogs and 36 cats. Influenza A virus RNA was detected in four wild birds (1.6%): two partridges and two mallards. According to the assay-specific classification recorded in the source dataset, 34 sera were reactive, 14 were doubtful, and 208 were non-reactive. All SARS-CoV-2 RT-qPCR-positive samples were ELISA-non-reactive; all reactive or doubtful ELISA results occurred among RT-qPCR-negative animals. Dogs and cats did not differ significantly in SARS-CoV-2 RT-qPCR positivity, ELISA reactivity, or Ct distributions. Because the ELISA had not been formally validated for the animal species studied, reactivity was not interpreted as confirmed SARS-CoV-2 seropositivity. The archived 2022–2023 dataset therefore provides a historical baseline for multispecies respiratory-virus surveillance in Kazakhstan and supports cautious integration of molecular and serological data.
- 4 November 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (11) , 2542
Open AccessIntegrated Molecular and Serological Epizootic Monitoring of SARS-CoV-2 and Influenza A Virus in Animals in Kazakhstan
Respiratory viruses with broad host ranges are relevant to veterinary epidemiology, biological safety, and One Health surveillance. This retrospective study integrated companion-animal and wildlife records to examine two complementary surveillance questions: SARS-CoV-2 detection in dogs and cats with close human contact, and influenza A virus detection across a broader multispecies panel that included wild birds. We analyzed 256 archived animal samples collected in Kazakhstan during 2022–2023, comprising 158 dogs, 76 cats, and 22 animals of other domestic and wild species. A previously developed in-house multiplex RT-qPCR assay was used to detect SARS-CoV-2 and influenza A virus RNA, and a previously developed in-house SM-antigen-based ELISA was used to assess SARS-CoV-2-associated serum reactivity. SARS-CoV-2 RNA was detected in 104/256 samples (40.6%; 95% CI, 34.8–46.7), including 68 dogs and 36 cats. Influenza A virus RNA was detected in four wild birds (1.6%): two partridges and two mallards. According to the assay-specific classification recorded in the source dataset, 34 sera were reactive, 14 were doubtful, and 208 were non-reactive. All SARS-CoV-2 RT-qPCR-positive samples were ELISA-non-reactive; all reactive or doubtful ELISA results occurred among RT-qPCR-negative animals. Dogs and cats did not differ significantly in SARS-CoV-2 RT-qPCR positivity, ELISA reactivity, or Ct distributions. Because the ELISA had not been formally validated for the animal species studied, reactivity was not interpreted as confirmed SARS-CoV-2 seropositivity. The archived 2022–2023 dataset therefore provides a historical baseline for multispecies respiratory-virus surveillance in Kazakhstan and supports cautious integration of molecular and serological data.
- Open Access
- 6 October 2026
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 3,p. 322-332
STABILITY OF AN ELISA TEST SYSTEM BASED ON A RECOMBINANT CHIMERIC SM PROTEIN FOR THE DETECTION OF ANTIBODIES TO SARS-COV-2 UNDER DIFFERENT TEMPERATURE CONDITIONS
Assessment of the stability of kit components is a critical step in the development of enzyme-linked immunosorbent assay (ELISA) systems, as it directly determines the accuracy and reproducibility of diagnostic results during storage and routine use. In the present study, the stability and reproducibility of a newly developed ELISA test system based on the recombinant chimeric SM protein were evaluated under different temperature conditions. The stability of the kit components was assessed by monitoring changes in the analytical signal, expressed as optical density (OD), and the variability of replicate measurements, expressed as the coefficient of variation (CV, %), over a controlled period at -20ºC, 4ºC, 22ºC, and 37ºC. The results demonstrated that the stability of the developed ELISA test system was strongly temperature-dependent. Standard refrigerated storage at 4ºC was identified as the optimal condition, providing the highest preservation of the analytical signal, with 81.3% of the initial signal retained (OD₄₅₀ = 1.933), while maintaining high reproducibility (CV = 1.74%), consistently below the predefined acceptance threshold of ≤5%. Storage at -20ºC showed notable limitations. Despite maintaining a relatively high analytical signal (OD₄₅₀ = 1.623) and 68.2% residual activity, freezing and thawing of the reagents resulted in increased analytical variability (CV = 5.56%), exceeding the established acceptance criterion. Exposure to elevated temperatures of 22ºC and 37ºC had a pronounced detrimental effect on test-system stability, resulting in degradation of protein components and a loss of more than 65% of the initial activity. These findings demonstrate that, to ensure long-term preservation of the sensitivity, specificity, and reproducibility of the developed ELISA diagnostic kit, storage at 4ºC under properly maintained cold-chain conditions is an essential technological requirement.
- 6 October 2026
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 3,p. 322-332
Open AccessSTABILITY OF AN ELISA TEST SYSTEM BASED ON A RECOMBINANT CHIMERIC SM PROTEIN FOR THE DETECTION OF ANTIBODIES TO SARS-COV-2 UNDER DIFFERENT TEMPERATURE CONDITIONS
Assessment of the stability of kit components is a critical step in the development of enzyme-linked immunosorbent assay (ELISA) systems, as it directly determines the accuracy and reproducibility of diagnostic results during storage and routine use. In the present study, the stability and reproducibility of a newly developed ELISA test system based on the recombinant chimeric SM protein were evaluated under different temperature conditions. The stability of the kit components was assessed by monitoring changes in the analytical signal, expressed as optical density (OD), and the variability of replicate measurements, expressed as the coefficient of variation (CV, %), over a controlled period at -20ºC, 4ºC, 22ºC, and 37ºC. The results demonstrated that the stability of the developed ELISA test system was strongly temperature-dependent. Standard refrigerated storage at 4ºC was identified as the optimal condition, providing the highest preservation of the analytical signal, with 81.3% of the initial signal retained (OD₄₅₀ = 1.933), while maintaining high reproducibility (CV = 1.74%), consistently below the predefined acceptance threshold of ≤5%. Storage at -20ºC showed notable limitations. Despite maintaining a relatively high analytical signal (OD₄₅₀ = 1.623) and 68.2% residual activity, freezing and thawing of the reagents resulted in increased analytical variability (CV = 5.56%), exceeding the established acceptance criterion. Exposure to elevated temperatures of 22ºC and 37ºC had a pronounced detrimental effect on test-system stability, resulting in degradation of protein components and a loss of more than 65% of the initial activity. These findings demonstrate that, to ensure long-term preservation of the sensitivity, specificity, and reproducibility of the developed ELISA diagnostic kit, storage at 4ºC under properly maintained cold-chain conditions is an essential technological requirement.
- Open Access
- 24 September 2026
- Published by Research Institute for Biological Safety Problems in Biosafety and Biotechnology
- Vol. 1 (26) , 17-39
IN VITRO CULTIVATION OF TREPONEMA PALLIDUM: FROM THE RABBIT MODEL TO HUMAN CELL-BASED SYSTEMS
Treponema pallidum subsp. pallidum is the causative agent of syphilis, a socially significant human infection whose incidence continues to increase in many regions of the world. Despite the availability of effective antibacterial therapy, investigation of the biology of this pathogen has long been limited by the inability to maintain its stable growth under artificial conditions. Historically, laboratory strains of T. pallidum have been maintained mainly by intratesticular passage in laboratory rabbits, which is associated with bioethical, technological and regulatory limitations. The aim of this review is to systematize current data on the development of T. pallidum in vitro cultivation systems, from the rabbit model and early tissue cultures to the Sf1Ep platform, direct isolation of modern clinical strains and the emergence of human cell-based systems. The review discusses the biological factors that make T. pallidum difficult to cultivate, including genome reduction, limited metabolic capacity, dependence on host cells and oxygen sensitivity. Long-term co-cultivation with rabbit epithelial Sf1Ep cells in TpCM-2 medium is considered a key technological stage in experimental treponemology. It is concluded that in vitro cultivation of T. pallidum should be regarded as a promising scientific and technological platform for studying pathogen physiology, host-cell interactions, antimicrobial susceptibility, reduction of dependence on animal models and development of biosafe experimental approaches.
- 24 September 2026
- Published by Research Institute for Biological Safety Problems in Biosafety and Biotechnology
- Vol. 1 (26) , 17-39
Open AccessIN VITRO CULTIVATION OF TREPONEMA PALLIDUM: FROM THE RABBIT MODEL TO HUMAN CELL-BASED SYSTEMS
Treponema pallidum subsp. pallidum is the causative agent of syphilis, a socially significant human infection whose incidence continues to increase in many regions of the world. Despite the availability of effective antibacterial therapy, investigation of the biology of this pathogen has long been limited by the inability to maintain its stable growth under artificial conditions. Historically, laboratory strains of T. pallidum have been maintained mainly by intratesticular passage in laboratory rabbits, which is associated with bioethical, technological and regulatory limitations. The aim of this review is to systematize current data on the development of T. pallidum in vitro cultivation systems, from the rabbit model and early tissue cultures to the Sf1Ep platform, direct isolation of modern clinical strains and the emergence of human cell-based systems. The review discusses the biological factors that make T. pallidum difficult to cultivate, including genome reduction, limited metabolic capacity, dependence on host cells and oxygen sensitivity. Long-term co-cultivation with rabbit epithelial Sf1Ep cells in TpCM-2 medium is considered a key technological stage in experimental treponemology. It is concluded that in vitro cultivation of T. pallidum should be regarded as a promising scientific and technological platform for studying pathogen physiology, host-cell interactions, antimicrobial susceptibility, reduction of dependence on animal models and development of biosafe experimental approaches.
- Open Access
- 28 July 2026
- Published by MDPI AG in Methods and Protocols
- Vol. 9 (4) , 113
Single Radial Immunodiffusion (SRID) Assay for Quantitative Determination of Recombinant SOD Protein in a Brucellosis Vaccine Candidate: Method Development and Validation
Recombinant superoxide dismutase (SOD) protein is a promising antigen candidate for brucellosis vaccines, and its quantitative determination is essential for vaccine quality control, standardization, and regulatory compliance. Although enzyme-linked immunosorbent assay (ELISA) is widely used for antigen quantification, its application to vaccine formulations may be limited due to chemical modifications of antigenic determinants occurring during detoxification and adjuvantation processes. Therefore, alternative analytical methods, such as single radial immunodiffusion (SRID), which enable direct antigen quantification independent of antigenic determinant modifications, represent valuable tools for vaccine analysis. The aim of this study was to develop and validate a single radial immunodiffusion (SRID) assay for the quantitative determination of recombinant SOD protein and to obtain hyperimmune sera in sheep. Sheep were immunized with recombinant SOD protein formulated with aluminum hydroxide or AddaS03 adjuvants. Antibody responses were evaluated using agar gel immunodiffusion (AGID) and enzyme-linked immunosorbent assay (ELISA). Immunization with aluminum hydroxide induced higher antibody titers than AddaS03. By day 42, ELISA titers reached 1:25,600 in the aluminum hydroxide group compared with 1:3200 in the AddaS03 group. The obtained hyperimmune sera were used for SRID assay development. The optimized SRID assay demonstrated high reproducibility and specificity, with no cross-reactivity against unrelated proteins. A linear relationship was observed between the square of the precipitation ring diameter (D2) and antigen concentration (R2 = 0.956–0.989). The assay showed a limit of detection of 0.312 μg/mL, a linear range of 0.625–10 μg/mL, high precision (CV < 2%), and robustness under varying analytical conditions. The developed SRID assay represents a specific, reproducible, and robust tool for quantitative control of recombinant SOD protein in vaccine formulations.
- 28 July 2026
- Published by MDPI AG in Methods and Protocols
- Vol. 9 (4) , 113
Open AccessSingle Radial Immunodiffusion (SRID) Assay for Quantitative Determination of Recombinant SOD Protein in a Brucellosis Vaccine Candidate: Method Development and Validation
Recombinant superoxide dismutase (SOD) protein is a promising antigen candidate for brucellosis vaccines, and its quantitative determination is essential for vaccine quality control, standardization, and regulatory compliance. Although enzyme-linked immunosorbent assay (ELISA) is widely used for antigen quantification, its application to vaccine formulations may be limited due to chemical modifications of antigenic determinants occurring during detoxification and adjuvantation processes. Therefore, alternative analytical methods, such as single radial immunodiffusion (SRID), which enable direct antigen quantification independent of antigenic determinant modifications, represent valuable tools for vaccine analysis. The aim of this study was to develop and validate a single radial immunodiffusion (SRID) assay for the quantitative determination of recombinant SOD protein and to obtain hyperimmune sera in sheep. Sheep were immunized with recombinant SOD protein formulated with aluminum hydroxide or AddaS03 adjuvants. Antibody responses were evaluated using agar gel immunodiffusion (AGID) and enzyme-linked immunosorbent assay (ELISA). Immunization with aluminum hydroxide induced higher antibody titers than AddaS03. By day 42, ELISA titers reached 1:25,600 in the aluminum hydroxide group compared with 1:3200 in the AddaS03 group. The obtained hyperimmune sera were used for SRID assay development. The optimized SRID assay demonstrated high reproducibility and specificity, with no cross-reactivity against unrelated proteins. A linear relationship was observed between the square of the precipitation ring diameter (D2) and antigen concentration (R2 = 0.956–0.989). The assay showed a limit of detection of 0.312 μg/mL, a linear range of 0.625–10 μg/mL, high precision (CV < 2%), and robustness under varying analytical conditions. The developed SRID assay represents a specific, reproducible, and robust tool for quantitative control of recombinant SOD protein in vaccine formulations.
- Open Access
Bacteriophage-Based Therapeutics for Bacterial Sexually Transmitted Infections: From Biological Barriers to Translational Strategies
Bacterial sexually transmitted and sexually associated infections remain a major global health concern, increasingly complicated by antimicrobial resistance and the limited effectiveness of existing therapies. In this context, bacteriophage-based and phage-derived approaches have re-emerged as potential alternative antibacterial strategies. This narrative review examines their applicability across key bacterial pathogens associated with sexually transmitted infections, including Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Treponema pallidum and biofilm-associated bacterial vaginosis, with a particular focus on pathogen-specific biological barriers. Available evidence indicates that the success of phage-based interventions is strongly dependent on factors such as intracellular localisation, structural characteristics of the bacterial envelope and the presence of polymicrobial biofilms. While phage-derived platforms, including endolysins, depolymerases and engineered phages, demonstrate antibacterial activity in experimental settings, their effectiveness is uneven across different pathogens. Biofilm-associated infections appear more accessible to these approaches, whereas intracellular and structurally atypical bacteria are currently considered more challenging targets based on available mechanistic and experimental evidence. These observations highlight the need for pathogen-specific engineering strategies and delivery systems. Overall, phage-based therapeutics in this field should be considered within a framework that integrates biological constraints with targeted antimicrobial design.
Open AccessBacteriophage-Based Therapeutics for Bacterial Sexually Transmitted Infections: From Biological Barriers to Translational Strategies
Bacterial sexually transmitted and sexually associated infections remain a major global health concern, increasingly complicated by antimicrobial resistance and the limited effectiveness of existing therapies. In this context, bacteriophage-based and phage-derived approaches have re-emerged as potential alternative antibacterial strategies. This narrative review examines their applicability across key bacterial pathogens associated with sexually transmitted infections, including Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Treponema pallidum and biofilm-associated bacterial vaginosis, with a particular focus on pathogen-specific biological barriers. Available evidence indicates that the success of phage-based interventions is strongly dependent on factors such as intracellular localisation, structural characteristics of the bacterial envelope and the presence of polymicrobial biofilms. While phage-derived platforms, including endolysins, depolymerases and engineered phages, demonstrate antibacterial activity in experimental settings, their effectiveness is uneven across different pathogens. Biofilm-associated infections appear more accessible to these approaches, whereas intracellular and structurally atypical bacteria are currently considered more challenging targets based on available mechanistic and experimental evidence. These observations highlight the need for pathogen-specific engineering strategies and delivery systems. Overall, phage-based therapeutics in this field should be considered within a framework that integrates biological constraints with targeted antimicrobial design.
- Open Access
- 22 December 2025
- Published by MDPI AG in Methods and Protocols
- Vol. 9 (1) , 4
Development of an ELISA Using Recombinant Chimeric SM Protein for Serological Detection of SARS-CoV-2 Antibodies
The emergence and spread of coronavirus infections have created a necessity to develop serological methods for assessing population immunity. The enzyme-linked immunosorbent assay (ELISA) remains one of the most accessible and informative approaches for these purposes. The choice of recombinant proteins plays an important role in the sensitivity and specificity of the test system, and in this regard, the creation of a domestic ELISA based on the chimeric SM protein to the SARS-CoV-2 virus is relevant. In this work, a recombinant chimeric SM protein expressed in the E. coli system and purified using metal-affinity chromatography on Ni-NTA agarose was constructed and presented for the first time. An ELISA test system was developed and tested using panels of positive and negative sera, including samples obtained before the COVID-19 pandemic. The obtained sensitivity (90.48%) and specificity (93.65%) indicators with a ROC curve AUC = 0.9623 (OD450 = 0.213) indicate the diagnostic accuracy of the test system. The positive diagnostic ratio (LR+) = 14.25.0 indicates the reliability of a positive result. The domestically developed ELISA test system can be used for serological monitoring and assessment of the immune status of the population.
- 22 December 2025
- Published by MDPI AG in Methods and Protocols
- Vol. 9 (1) , 4
Open AccessDevelopment of an ELISA Using Recombinant Chimeric SM Protein for Serological Detection of SARS-CoV-2 Antibodies
The emergence and spread of coronavirus infections have created a necessity to develop serological methods for assessing population immunity. The enzyme-linked immunosorbent assay (ELISA) remains one of the most accessible and informative approaches for these purposes. The choice of recombinant proteins plays an important role in the sensitivity and specificity of the test system, and in this regard, the creation of a domestic ELISA based on the chimeric SM protein to the SARS-CoV-2 virus is relevant. In this work, a recombinant chimeric SM protein expressed in the E. coli system and purified using metal-affinity chromatography on Ni-NTA agarose was constructed and presented for the first time. An ELISA test system was developed and tested using panels of positive and negative sera, including samples obtained before the COVID-19 pandemic. The obtained sensitivity (90.48%) and specificity (93.65%) indicators with a ROC curve AUC = 0.9623 (OD450 = 0.213) indicate the diagnostic accuracy of the test system. The positive diagnostic ratio (LR+) = 14.25.0 indicates the reliability of a positive result. The domestically developed ELISA test system can be used for serological monitoring and assessment of the immune status of the population.
- Open Access
- 30 September 2025
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 3,p. 111-117
PREPARATION OF HYPERIMMUNE SERA FOR SARS-COV-2 VIRUS
Hyperimmune sera are a primary component of diagnostic test systems utilising enzyme immunoassay to identify specific antibodies against infectious disease pathogens. During diagnostic assay development, hyperimmune sera function as positive controls and enable the generation of standard curves for quantitative measurement of antibody levels. Furthermore, they can be used to assess the sensitivity and specificity of established test systems and to verify novel diagnostic approaches. The objective of this study was to produce hyperimmune serum against SARS-CoV-2. Purified and concentrated virus, in conjunction with adjuvants such as aluminium hydroxide or AddaS03, was employed to immunise animals. Consequently, specific sera exhibiting activity in ELISA at dilutions of 1:1600- 1:3200 and in the diffusion precipitation reaction (DPR) at 1:8–1:32 were acquired. The research demonstrated that the use of concentrated, pure SARS-CoV-2 for animal immunisation, supplemented with adjuvants, is a viable and efficacious approach for generating highly active antibodies.
- 30 September 2025
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 3,p. 111-117
Open AccessPREPARATION OF HYPERIMMUNE SERA FOR SARS-COV-2 VIRUS
Hyperimmune sera are a primary component of diagnostic test systems utilising enzyme immunoassay to identify specific antibodies against infectious disease pathogens. During diagnostic assay development, hyperimmune sera function as positive controls and enable the generation of standard curves for quantitative measurement of antibody levels. Furthermore, they can be used to assess the sensitivity and specificity of established test systems and to verify novel diagnostic approaches. The objective of this study was to produce hyperimmune serum against SARS-CoV-2. Purified and concentrated virus, in conjunction with adjuvants such as aluminium hydroxide or AddaS03, was employed to immunise animals. Consequently, specific sera exhibiting activity in ELISA at dilutions of 1:1600- 1:3200 and in the diffusion precipitation reaction (DPR) at 1:8–1:32 were acquired. The research demonstrated that the use of concentrated, pure SARS-CoV-2 for animal immunisation, supplemented with adjuvants, is a viable and efficacious approach for generating highly active antibodies.
- Open Access
- 24 June 2025
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 2,p. 17-25
OBTAINING SPECIFIC ANIMAL BLOOD SERUM TO THE CAUSATIVE AGENT OF EPIZOOTIC LYMPHANGOITIS IN EQUINES
Selection of animals for obtaining specific blood serums is an important step. Before the start of immunization, blood samples were taken from potential donors for testing using enzyme-linked immunosorbent assay (ELISA), diffusion precipitation reaction (DPR) and prolonged complement fixation reaction (PCFR) to detect antibodies to other viral and bacterial infections. It has been experimentally established that antibodies to the pathogens of equine epizootic lymphangitis (ELL), peste des petits ruminants, sheep pox and anthrax were not detected in the blood serum of rabbits, goats and sheep used to obtain specific blood serum. This is necessary to exclude possible cross-reactions when using the obtained immune sera in serological reactions. To obtain specific sera in the experiment, purified antigens of the cultures of strains “T”, “3724 K” and “3730 K” of the causative agent of ELL were used, which have activity in the RDP within the range of 1:16-1:32 and in the RSC of at least 1:40-1:80. To obtain a specific serum, 11 immunization schemes were tested, which differed in the methods of immunization, the concentration and volume of the administered antigen, the intervals between administrations, and the different strains of diseases used to administer them. Experimentally, we managed to obtain specific and active serums from rabbits, goats and sheep. The activity of immune serums in rabbit #6 DPR was 1:32, in PCFR – 1:128, goat #1 in DPR – 1:16, in PCFR 1:64 and sheep #1 in DPR 1:8, in PCFR 1:32. These diagnostic serums will be used to establish laboratory methods for detecting the antigen of the ELL pathogen in the biological materials being studied.
- 24 June 2025
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 2,p. 17-25
Open AccessOBTAINING SPECIFIC ANIMAL BLOOD SERUM TO THE CAUSATIVE AGENT OF EPIZOOTIC LYMPHANGOITIS IN EQUINES
Selection of animals for obtaining specific blood serums is an important step. Before the start of immunization, blood samples were taken from potential donors for testing using enzyme-linked immunosorbent assay (ELISA), diffusion precipitation reaction (DPR) and prolonged complement fixation reaction (PCFR) to detect antibodies to other viral and bacterial infections. It has been experimentally established that antibodies to the pathogens of equine epizootic lymphangitis (ELL), peste des petits ruminants, sheep pox and anthrax were not detected in the blood serum of rabbits, goats and sheep used to obtain specific blood serum. This is necessary to exclude possible cross-reactions when using the obtained immune sera in serological reactions. To obtain specific sera in the experiment, purified antigens of the cultures of strains “T”, “3724 K” and “3730 K” of the causative agent of ELL were used, which have activity in the RDP within the range of 1:16-1:32 and in the RSC of at least 1:40-1:80. To obtain a specific serum, 11 immunization schemes were tested, which differed in the methods of immunization, the concentration and volume of the administered antigen, the intervals between administrations, and the different strains of diseases used to administer them. Experimentally, we managed to obtain specific and active serums from rabbits, goats and sheep. The activity of immune serums in rabbit #6 DPR was 1:32, in PCFR – 1:128, goat #1 in DPR – 1:16, in PCFR 1:64 and sheep #1 in DPR 1:8, in PCFR 1:32. These diagnostic serums will be used to establish laboratory methods for detecting the antigen of the ELL pathogen in the biological materials being studied.
- 26 March 2025
- Published by Research and Production Center for Microbiology and Virology in МИКРОБИОЛОГИЯ ЖӘНЕ ВИРУСОЛОГИЯ
- No. 1(48),p. 153-167
OPTIMIZATION OF PCR PARAMETERS FOR AMPLIFICATION OF NEWCASTLE DISEASE VIRUS GENES
This article presents the results of selecting oligonucleotide primers and optimizing conditions for conducting a reverse transcription polymerase chain reaction (RT-PCR) to detect Newcastle disease virus genes. The choice of target genes is based on the fact that the virus genome determines potential approaches for using it as a vector for antigen delivery in the development of safe and effective vaccines. The virus offers several advantages: it is a type species of the avian orthoavulavirus-1 (AOaV-1) group within the Paramyxoviridae family, possesses an envelope, and has a non-segmented negative-strand RNA genome, which allows for the insertion of foreign genes up to approximately 5 kbp. Three pairs of oligonucleotide primers were selected and synthesized to generate specific PCR products for the targeted genes. The performance of the developed primers was assessed using a typical temperature-time amplification program in the PCR setup. The resulting amplicons were analyzed by electrophoresis on a 1.7% agarose gel with ethidium bromide staining. The designed primers cover the full nucleotide sequences of each gene: M (1095 bp), F (1566 bp), and HN (1751 bp), with the corresponding molecular weights В данной статье представлены результаты по выбору олигонуклеотидных праймеров и оптимизации условий проведения полимеразной цепной реакции с обратной транскрипцией (ОТ-ПЦР) для детекции генов вируса болезни Ньюкасла. Выбор целевых генов вируса обусловлен тем, что в целом геном вируса определяют возможные подходы к использованию его в качестве вектора для доставки антигенов при разработке безопасных и эффективных вакцин и имеет ряд преимуществ: является типовым видом группы птичьего ортоавулавируса-1 (AOaV-1) семейства Paramyxoviridae, имеет оболочку и несегментированный РНК-геном с отрицательной цепью, который позволяет вставлять чужеродные гены (до ~5 т.п.н.). Подобраны и синтезированы 3 пары олигонуклеотидных праймеров для наработки специфических ПЦР продуктов исследованных генов. С помощью постановки полимеразной цепной реакции с использованием типичной программы температурно-временного режима амплификаций были проверены работоспособность разработанных праймеров. Полученные амплификоны были проанализированы с помощью электрофоретического метода на 1,7 %-ном агарозном геле с бромистым этидием. Сконструированные праймеры охватывают нуклеотидную последовательность каждого гена: M, F, HN полностью с соответствующими молекулярными массами: п.о. 1095, п.о. 1566, п.о. 1751.
- 26 March 2025
- Published by Research and Production Center for Microbiology and Virology in МИКРОБИОЛОГИЯ ЖӘНЕ ВИРУСОЛОГИЯ
- No. 1(48),p. 153-167
OPTIMIZATION OF PCR PARAMETERS FOR AMPLIFICATION OF NEWCASTLE DISEASE VIRUS GENES
This article presents the results of selecting oligonucleotide primers and optimizing conditions for conducting a reverse transcription polymerase chain reaction (RT-PCR) to detect Newcastle disease virus genes. The choice of target genes is based on the fact that the virus genome determines potential approaches for using it as a vector for antigen delivery in the development of safe and effective vaccines. The virus offers several advantages: it is a type species of the avian orthoavulavirus-1 (AOaV-1) group within the Paramyxoviridae family, possesses an envelope, and has a non-segmented negative-strand RNA genome, which allows for the insertion of foreign genes up to approximately 5 kbp. Three pairs of oligonucleotide primers were selected and synthesized to generate specific PCR products for the targeted genes. The performance of the developed primers was assessed using a typical temperature-time amplification program in the PCR setup. The resulting amplicons were analyzed by electrophoresis on a 1.7% agarose gel with ethidium bromide staining. The designed primers cover the full nucleotide sequences of each gene: M (1095 bp), F (1566 bp), and HN (1751 bp), with the corresponding molecular weights В данной статье представлены результаты по выбору олигонуклеотидных праймеров и оптимизации условий проведения полимеразной цепной реакции с обратной транскрипцией (ОТ-ПЦР) для детекции генов вируса болезни Ньюкасла. Выбор целевых генов вируса обусловлен тем, что в целом геном вируса определяют возможные подходы к использованию его в качестве вектора для доставки антигенов при разработке безопасных и эффективных вакцин и имеет ряд преимуществ: является типовым видом группы птичьего ортоавулавируса-1 (AOaV-1) семейства Paramyxoviridae, имеет оболочку и несегментированный РНК-геном с отрицательной цепью, который позволяет вставлять чужеродные гены (до ~5 т.п.н.). Подобраны и синтезированы 3 пары олигонуклеотидных праймеров для наработки специфических ПЦР продуктов исследованных генов. С помощью постановки полимеразной цепной реакции с использованием типичной программы температурно-временного режима амплификаций были проверены работоспособность разработанных праймеров. Полученные амплификоны были проанализированы с помощью электрофоретического метода на 1,7 %-ном агарозном геле с бромистым этидием. Сконструированные праймеры охватывают нуклеотидную последовательность каждого гена: M, F, HN полностью с соответствующими молекулярными массами: п.о. 1095, п.о. 1566, п.о. 1751.